Treatment of corona virus
Vaccination of COVID-19

Treatment of corona virus – Doctors and scientists have been studying existing antivirals to see if there could be an effective treatment for this new disease. An antiviral drug called Remdesivir was originally developed to fight the Ebola virus and has been in the treatment arm of several studies investigating whether it plays a role in treating COVID-19. 

Since Remdesivir is only available as an intravenous drug, clinical research studies are limited to hospitals. The Food and Drug Administration has approved the use of Desavir for compassionate use, meaning the treatment can be approved for patients who need medical care in the United States and other countries. 

The Chicago hospital where severe Covid 19 patients were treated with Gilead Sciences “antiviral drug Remdesivir in a closely watched clinical trial has seen a rapid recovery from fever and respiratory illnesses, with nearly all patients discharged in less than a week, STAT has learned. Medical news site STAT reported that the U.S. Centers for Disease Control and Prevention (CDC) is investigating whether deavir can reduce complications and shorten disease progression in 19 patients. Dr. Michael D. Miller, an infectious disease professor at the University of Chicago Medical Center who has treated early and severe cases of CO VID 19, told the science journal Science that patients get better as soon as they get the drug. 

The whole world is awaiting the results of Gilead’s clinical trial, and a positive result would likely lead to accelerated approval of the drug by the US Food and Drug Administration. Remdesivir is the first drug to have been shown by laboratory tests to cause the novel coronavirus (COVID-19). 

If it is safe and effective, it could become the first approved drug for the disease. The drug Gilead Sciences, which was originally tested on people with Ebola, has not been shown to be effective against Ebola. But it has been redirected to see if it can treat COVID-19, and laboratory studies have shown that the drug inhibits the growth of the new coronavirus Covid 19 in the blood of patients with the Ebola virus. 

In a petri dish, Remdesivir can prevent human cells from becoming infected with both SARS and CoV-2, according to a letter published in the journal Nature in February. Gilead Sciences developed it to treat the deadly hemorrhagic fever that occurred in West Africa in 2014, but it is too early to know whether the drug works or not. Scientists are now testing the drug in the treatment of coronavirus patients, not just against the Ebola virus COVID-19. 

Although there is no vaccine or cure for Covid-19, the drug has shown very promising early results in the treatment of coronavirus patients. Remdesivir achieved encouraging results earlier this year when it showed promising results in the prevention and treatment of the MERS coronvirus in macaques and monkeys.

US scientists are testing a drug to treat Ebola patients on people who have been hospitalized with the virus as well as patients with other corona viruses.

The drug, known as Remdesivir, is considered the most promising by World Health Organization scientists, while another study on the treatment and prevention of Covid-19 with antimalarial drugs is being investigated. The first results of the international clinical trial show a significant improvement in the recovery time of patients with coronaviruses from the Ebola virus. Preliminary results suggest that 11.6% of those in a group receiving the drug faced 6.5% in a placebo group, “said Dr. Michael D. Kowalski, lead author of the study and professor of infectious diseases at Johns Hopkins University in Baltimore, Maryland. Patients who received a dose of 1,000 milligrams per day (mg / dl) had recovery times that were nearly a third faster than placebo, he said. 

Hopes for the drug were revived last year when the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC) said data from a clinical trial showed that Remdesivir had a significantly shorter recovery time in patients with coronaviruses from the Ebola virus. 

A few hours after Fauci’s announcement, the prestigious medical journal Lancet published a study from China that found that Remdesivir did not accelerate recovery of Covid-19 or reduce deaths from Covid-19 compared to placebo in hospital patients. 

Remdesivir, which is administered by intravenous infusion, was originally developed by pharmaceutical company Gilead Sciences to treat Ebola.

Although initially promising, it did not prove as effective as other Ebola treatments, and research was stopped. However, laboratory studies have shown that Remdesivir may be effective against the virus causing the current COVID-19 pandemic. Although the figures are in the works, there is no specific treatment for COVID-19, including experimental antivirals that can attack this virus, as well as existing drugs that target other viruses, such as HIV, that have shown promise in treatment. 

An experimental antiviral drug from biotechnology company Gilead Sciences has taken much of the limelight, but the drug has essentially not received approval and has not been used in the United States for more than a year, despite being used in a small number of people in Africa and other parts of Asia. 


Leave a Reply

Your email address will not be published. Required fields are marked *